Results 31 to 40 of about 178,517 (322)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Leukemia, 2020
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval.
T. Wen, Jin-song Wang, Yuankai Shi, H. Qian, Peng Liu   +4 more
semanticscholar   +1 more source

Targeting Bruton's tyrosine kinase in B cell malignancies [PDF]

Nature Reviews Cancer, 2014
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in clinical studies.
R. Hendriks, S. Yuvaraj, Laurens P. Kil
semanticscholar   +5 more sources

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & Rheumatology, 2021
Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter,
D. Isenberg, R. Furie, N. S. Jones, P. Guibord, J. Galanter, Chin H Lee, A. Mcgregor, Balazs Toth, J. Rae, O. Hwang, Rupal H Desai, A. Lokku, N. Ramamoorthi, J. Hackney, P. Miranda, Viviane A de Souza, J. Jaller-Raad, A. Maura Fernandes, Rodrigo Garcia Salinas, L. Chinn, M. Townsend, A. Morimoto, K. Tuckwell   +22 more
semanticscholar   +1 more source

Managing toxicities of Bruton tyrosine kinase inhibitors [PDF]

Hematology, 2020
Abstract Inhibition of Bruton’s tyrosine kinase (BTK) has revolutionized the treatment landscape for patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal B-cell receptor signaling, BTK inhibitors (BTKis) impair cell proliferation, migration, and activation of NF-κB.
Nicole Lamanna, Andrew Lipsky
openaire   +2 more sources

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

Медицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina, N. B. Serebryanaya, T. V. Glazanova, M. A. Mikhalyova, S. V. Voloshin   +4 more
doaj   +1 more source

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Clinical Cancer Research, 2020
Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse is poor, and treatment choices are limited.
Yuqin Song, K. Zhou, D. Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, J. Ji, Wei Xu, Jie Jin, F. Lv, R. Feng, Sujun Gao, Haiyi Guo, Lei Zhou, R. Elstrom, Jane E. Huang, W. Novotny, R. Wei, Jun Zhu   +19 more
semanticscholar   +1 more source

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

New England Journal of Medicine, 2014
BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been ...
J. Woyach, R. Furman, Ta-Ming Liu, H. Ozer, M. Zapatka, A. Ruppert, L. Xue, Daniel Li, S. Steggerda, M. Versele, S. Dave, Jenny Zhang, A. S. Yilmaz, S. Jaglowski, K. Blum, A. Lozanski, G. Lozanski, D. James, J. Barrientos, P. Lichter, S. Stilgenbauer, J. Buggy, B. Chang, A. Johnson, J. Byrd   +24 more
semanticscholar   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

PLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui, Sarah A Meadows, Rick A Sorensen, Zhi-Hua Cui, Kathleen S Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey L Tannheimer   +9 more
doaj   +1 more source

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Turkish Journal of Hematology, 2021
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviation:
Anıl Tombak, Funda Pepedil Tanrıkulu, Salih Sertaç Durusoy, Hüseyin Derya Dinçyürek, Emin Kaya, Elif Gülsüm Ümit, İrfan Yavaşoğlu, Özgür Mehtap, Burak Deveci, Mehmet Ali Özcan, Hatice Terzi, Müfide Okay, Nilgün Sayınalp, Mehmet Yılmaz, Vahap Okan, Alperen Kızıklı, Ömer Özcan, Güven Çetin, Sinan Demircioğlu, İsmet Aydoğdu, Güray Saydam, Eren Arslan Davulcu, Gül İlhan, Mehmet Ali Uçar, Gülsüm Özet, Seval Akpınar, Burhan Turgut, İlhami Berber, Erdal Kurtoğlu, Mehmet Sönmez, Derya Selim Batur, Rahşan Yıldırım, Vildan Özkocaman, Ahmet Kürşad Güneş, Birsen Sahip, Şehmus Ertop, Olga Meltem Akay, Abdülkadir Baştürk, Mehmet Hilmi Doğu, Aydan Akdeniz, Ali Ünal, Ahmet Seyhanlı, Emel Gürkan, Demet Çekdemir, Burhan Ferhanoğlu   +44 more
doaj   +1 more source